Business
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer's disease (AD) who was treated for t
About this update from Tiziana Life Sciences Ltd
[{"type":"image","alt":"Tiziana Life Sciences Ltd.","displaySize":"","headline":null,"caption":"Tiziana Life Sciences Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":264,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3k64r3yQgq2ENSiAhwIMCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947","width":264,"height":60}},"lazy":false},{"type":"text","content":"NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer's disease (AD) who was treated for three months with intranasal foralumab under an expanded access program. The microglial TSPO PET scan revealed a significant decrease in microglia activation, a key indicator of neuroinflammation associated with Alzheimer's disease progression.","length":751,"tagName":"p"},{"type":"text","content":"Figure 1.","length":9,"tagName":"p"},{"type":"image","alt":"Tiziana Life Sciences Plc","displaySize":"","headline":null,"caption":"Tiziana Life Sciences Plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":624,"height":429,"url":"https://media.zenfs.com/en/globenewswire.com/0a1069ffc9ab594989f4809b6205290f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LknFLxcLOoyu3.APV1q.5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0a1069ffc9ab594989f4809b6205290f","width":624,"height":429}}},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"Figure 1. Decrease in PET signal after foralumab treatment (bottom row) as compared to pre-treatment baseline (top-row). Adapted from Singhal T et al. Clinical Nuclear Medicine 2025 (in press).","length":193,"tagName":"p"},{"type":"text","content":"The above data was presented by Dr. Howard Weiner at the 2025 AD/PD Conference in Vienna and is featured in the AlzForum. The ...